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PAD patients who undergo more invasive revascular-
ization procedures are more likely to decrease or quit
smoking
Sareh Rajaee, Edward J. Marcaccio, Wilfred I. Carney, Tze
Tec Chong, Manuel Garcia-Toca, Jeffrey M. Slaiby. De-
partment of Vascular Surgery, Warren Alpert Medical
School at Brown University, Providence, RI
Objectives: To determine if PAD patients who un-
dergo surgical revascularization procedures are more likely
to change their smoking habits than those who undergo
percutaneous revascularization. This study assesses changes
in smoking habits following intervention via patient-an-
swered surveys and retrospective chart review.
Methods: Study participants included patients seen
between 2005 and 2010 and assigned ICD.9 code diagno-
ses of PVD, claudication, or PAD. 500 participants were
identified belonging to 1 of 3 intervention groups (medi-
cal, percutaneous, or surgical), of which 142 submitted
surveys. Here we present a preliminary analysis of 55 pa-
tients who were active smokers at the time of intervention.
An interrater reliability analysis using the Kappa statistic
was used to compare survey-reported and medical record
documented smoking habit change. A Fisher’s exact test
was used to compare smoking habit change among percu-
taneous and surgically treated groups. A logistic regression
analysis was performed to determine if surgical revascular-
ization independently predicts a decrease in smoking while
controlling for potential confounders. Historical elements
were extracted from themedical record and included: ABIs,
history of CAD, diabetes, COPD, stroke, alcohol use, and
marriage status.
Results: 36% (n20) of the patients underwent surgi-
cal revascularization and 42% (n23) underwent percuta-
neous revascularization. The Kappa value was 0.54 (p
0.001). 94% of the patients believed that smoking was a
significant contributor to their PAD. The Fisher’s exact test
revealed a higher proportion of patients who quit or cut
down on smoking after surgical intervention compared to
percutaneous intervention (95% vs 61%, p0.011). This
association remained after controlling for confounders (OR
0.02, 95% CI 0.001-0.47, p0.03).
Conclusions: Patients with PAD who undergo a more
invasive revascularization, such as surgical bypass, are more
likely to quit or cut down on smoking than those who
undergo percutaneous procedures.
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Duplex-Guided Office-Based Arterio-venous Fistula
Thrombectomy: A Novel Technique
Anil Hingorani, Division of Vascular Services, Maimonides
Medical Center, Brooklyn, NY
Objectives: Autologous arterial-venous accesses
(AVA) have been shown to be superior to the ones created
with synthetic material. Accordingly, several strategies have
been developed to extend the salvage rates for failing or
failed AVAs. We analyzed our aggressive approach to sal-
vaging acutely occluded AVAs in an office setting using
duplex scanning.
Methods: Over 12 months, 14 patients with acute
thrombosis of their AVA underwent 18 procedures for
salvage at our office. there were 10 (71%) radial-cephalic
and 4 (29%) brachial-cephalic fistulas. Presence of throm-
bus, as confirmed by preoperative duplex, served as the
indication for 16 (89%) of the cases. Acute thrombosis
during routine angioplasty was the indication for the re-
maining 2(11%) of the cases. Of the 14 patients, thrombus
was located at the perianastomotic AVF in 6 (43%), prx-
mid AVF in 6 (43%), mid AVF in 1 (7%), dist AVF in
1 (7%). Treatment included balloon dilation and masera-
tion (group A), 10(56%) or pharmaco-mechanical throm-
bectomy (group B), 8,(44%). Of the 18 procedures,
13 (72%) were successful.
Results: All patients were treated under duplex-guid-
ance alone. Full restoration of fistula flow was established in
14 cases (78%). Early re-thrombosis (1 mo patency)
occurred in 3 cases (17%), these patients received new
fistulas. From group A, 6 (60%) were successful. From
group B, 7 (88%) were successful. The 1 case that was
unsuccessful was the patient with a history of PCV. Of the
14 patients, 8 (57%) are currently on hemodialysis via fis-
tula. 3 patients (21%) had newly placed fistulas after failed
interventions. 2 patients (14%) are not on dialysis yet. 1
patient (7%) with PCV disorder is on dialysis via tesio.
Conclusions: This small series demonstrates that ultra-
sound alone can be not only be used as an important
diagnostic tool preoperatively but also to guide treatment
of acutely occluded arteriovenous fistulae.
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Safety and Efficiacy of Rapid Autologous Bone Marrow
Aspirate Concentrate for the Treatment of Critical
Limb Ischemia in Buerger’s Disease
Radhakrishnan Raju, Sivaraman G. Mani, Vijayaraghavan
Kuppu Sampath. Vascular Surgery, Sri Ramachandra Uni-
versity, Chennai, India
Objectives: Patients diagnosed with critical limb isch-
emia, have high risk of limb loss and a shortened life
expectancy. The end stage of this deteriorating disease
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usually leaves patients with no treatment options. Autolo-
gous bone marrow cells may have potential to reduce the
instances of amputation and improve quality of life for these
patients.
Methods: 49 patients with thromboangitis obliterans
resulting in CLI were treated with a composition of con-
centrated bone marrow nucleated cells. A total of 240 mL
of aspirate was processed using a point of care centrifuge
(Harvest Technologies, Plymouth, MA) to yield 40 mL of
treating volume. The patients were divided equally into two
treatment groups. Group 1 received forty 1 mL direct
intramuscular injections in the ischemic regions below the
knee and Group 2 received twenty 1 mL direct intramus-
cular injections below the knee and an intra-arterial infu-
sion of 20 mL down the SFA into the lower leg. An
evaluation of these patients was conducted at 12 and 26
weeks.
Results: All patients enrolled were men with the fol-
lowing demographics: mean age 44.9, all smokers. There
were six adverse events in each treatment group. None were
considered to be related to the biologic treatment. No
patients died. Limb salvage was 87.5% and all major end-
points showed statistically significant improvement over
baseline: Quality of Life assessment (Rand-36 question-
naire) p0.0009; perception of pain p0.0001; TcPO2
and ABI measurement p0.0001 & p 0.0003 respec-
tively. There was 100% reduction in pain medications.
Mean number of nucleated cells delivered 3.63x10. The
delivery method showed no statistical difference.
Conclusions: Based on these results, this bone marrow
composition may be considered safe and has shown poten-
tial to reduce amputation rates. This study has also shown
that both the methods of delivery are equally effective and
safe.
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Congestive Heart Failure with Systolic Dysfunction Is
Associated with Decreased Patency after Endovascular
Intervention for Symptomatic Peripheral Arterial Dis-
ease
Andrew J. Meltzer, Kathy A. Gallagher, Sikandar Z. Khan,
Peter Connolly, Francesco A. Aiello, In-Kyong Kim, Gau-
tam Shrikhande, Asad Kahn, James F. McKinsey. Vascular
Surgery, New York-Presbyterian Hospital, New York, NY
Objectives: Congestive heart failure (CHF) predicts
morbidity and mortality after treatment of peripheral arte-
rial disease. The impact on procedural success, however,
remains unknown. We hypothesized that CHF with re-
duced left ventricular ejection fraction (LVEF) results in a
diminished perfusion pressure and a low-flow state that
could predispose arterial interventions to fail.
Methods: A prospective database identified patients
with CHF who underwent endovascular arterial interven-
tion from 2004-2009. Demographics, co-morbidities, in-
tervention, LVEF, and outcomes were recorded. Patients
were followed clinically and by duplex ultrasound. Kaplan-
Meier survival analysis and Cox Regression were used.
Results: Of 1220 patients undergoing intervention,
271 patients (22%) with documented CHF underwent
intervention for claudication (23%) or critical limb ischemia
(CLI) (77%). Primary patency at 1 year was 51.92.5%
among those with CHF, compared to 64.61.3% in con-
trols (p0.001). In the setting of CHF, 1 year patency was
56.64.1% if LVEF40% vs 43.23.5% if LVEF40%
(p0.001). (Table 1). Among those with CLI, limb sal-
vage rates were equivalent between controls and patients
with CHF and LVEF40%, but worse with LVEF40%
(p0.01) and LVEF20% (p0.001).
Conclusions: CHF is an independent risk factor for
failure of endovascular intervention. Specifically, low LVEF
(40%) predicts loss of patency. The inverse association
between patency and LVEF needs further assessment.
Table 1. Primary Patency
Patency at
12 months
Patency at
24 months
Patency at
36 months
Control 64.6  1.3 53.1  1.4 47.5  1.6
CHF 51.9  2.5 42.8  2.7 38.5  2.8
LVEF40% 56.6  4.1 45.9  4.4 36.0  4.8
LVEF40% 43.2  3.5 26.9  3.7 16.8  4.9
P-Values
Control vs CHF .001* .001* .001*
Control vs CHF
(LVEF40%)
.001* .001* .001*
Control vs CHF
(LVEF40%)
0.03* 0.051 0.057
LVEF40% vs
LVEF40%
0.008* .001* .001*
*Statistically Significant.
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Video Presentation
Endovascular Management of an Aorto-Iliac Occlusion
Utilizing an IVUS Guided Re-entry Device
Ali Amin. Surgery, Reading Hospital and Medical Center,
Reading, PA
Background: 43 yr old female. pain bilateral lower
extremity for 8 months. Pain worse right side, can only
walk few feet. pain at night, chronic numbness right foot.
Hypertension, COPD, HIV smoker Absent femoral/
pedal pulses. ABI right .36 left .64 Abdominal duplex:
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